Vitruvias currently has 10 ongoing late-stage development projects.
1 First Cycle ANDA Approval in 2017.
3 ANDAs are awaiting approval.
5 ANDAs will be filed in 2017.
1 CBE-30 will be filed in 2018.
The Vitruvias product mix contains:
4 injectable projects.
3 topical projects.
2 oral solid projects.
1 oral solution project.
Nine of the ten projects are partnered.